Novo Nordisk submitted an oral version of semaglutide for weight loss to the FDA in 2024, and approval is expected to reshape access to GLP-1 therapy. The injectable Wegovy has a list price above $1,300 per month, and early reports suggest the Wegovy pill cost will land in the same neighborhood for the brand-name oral version. Rybelsus, the oral semaglutide currently approved for type 2 diabetes, provides a useful reference point for what to expect. For broader pricing context, see our healthcare costs guide.
Is the Wegovy Pill Approved Yet?
As of early 2026, injectable Wegovy remains the only FDA-approved version of semaglutide for chronic weight management. Novo Nordisk has submitted an oral weight-loss version for FDA review, and approval is anticipated, but the drug is not yet on pharmacy shelves under the Wegovy brand. Rybelsus, the currently approved oral semaglutide, is labeled only for type 2 diabetes at doses of 3, 7, and 14 mg.
A high-dose oral semaglutide (25 mg) was studied in OASIS-1, published in The Lancet, which showed roughly 15% body weight loss over 68 weeks. This is the formulation expected to reach US pharmacies as an oral Wegovy product.
Expected Pricing
Novo Nordisk has not officially announced the US price for the oral Wegovy formulation. Industry analysts expect the list price to match the injectable version at roughly $1,349 per month to avoid cannibalizing existing sales. Rybelsus at its highest dose (14 mg) currently runs about $1,020 to $1,100 per month at retail cash price, which is useful as a benchmark.
Wegovy Pill Cost With Insurance
If the pill version follows injectable Wegovy’s coverage patterns, commercial insurance copays will likely run $25 to $150 per month when the drug is on formulary. High-deductible plans may require full cash payment until the deductible is met.
Medicare coverage for oral Wegovy will depend on the indication. Part D statutorily excludes weight-loss drugs, but the cardiovascular MACE indication approved for injectable Wegovy in 2024 opened coverage for specific at-risk patients. See our article on does Medicare cover Wegovy for current rules.
Wegovy Pill Cost Without Insurance
Paying cash is likely to be expensive. If the oral Wegovy list price matches the injectable, expect $1,300 to $1,450 per month at retail. Annual cash cost would run $15,600 to $17,400. Novo Nordisk’s self-pay NovoCare program has discounted injectable Wegovy to about $499 per month, and a similar program may launch for the oral version.
Rybelsus as a Comparison
Rybelsus is useful for comparison because it is the only currently available oral semaglutide. According to GoodRx pricing data, Rybelsus 14 mg costs roughly $1,020 to $1,100 per month cash. Savings cards can reduce commercial insurance copays to as low as $10 for eligible patients. Our Rybelsus coupon article covers the discount options.
Keep in mind that Rybelsus 14 mg is the highest FDA-approved dose, and it is labeled only for diabetes. The oral weight-loss version is expected at higher doses (25 or 50 mg), which may carry a higher price.
Why Oral Formulations Cost More to Make
Oral semaglutide requires a special absorption enhancer called SNAC (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate) to survive the stomach and reach the small intestine. This adds cost to manufacturing compared to the injectable, which is one reason oral versions are not dramatically cheaper despite being convenient. CMS and manufacturer data suggest the formulation complexity directly impacts list pricing.
Ways to Reduce the Wegovy Pill Cost
Expected strategies, based on how injectable Wegovy is currently handled:
- Manufacturer savings card for commercially insured patients
- Self-pay program if Novo Nordisk launches one for the oral version
- Prior authorization with clear BMI and comorbidity documentation
- Pharmacy price comparison using GoodRx or similar tools
- Patient assistance programs for low-income uninsured individuals
Cash-Pay Alternatives
While waiting for oral Wegovy, patients may consider:
- Injectable Wegovy NovoCare self-pay at $499 per month
- Zepbound injectable at $349 to $499 per month through LillyDirect vials
- Ozempic when diabetes is the indication and a pill version is not needed
For comparisons, see our articles on Wegovy cost and Zepbound cost without insurance.
Frequently Asked Questions
Is there a Wegovy pill available now?
Injectable Wegovy remains the only FDA-approved formulation for chronic weight management as of early 2026. An oral version is under FDA review.
How much will the Wegovy pill cost?
Expected pricing is $1,300 to $1,450 per month at the list price, based on typical Novo Nordisk pricing patterns. Actual launch pricing has not been confirmed.
Is Rybelsus the same as oral Wegovy?
Rybelsus contains oral semaglutide, but at lower doses approved for type 2 diabetes. The oral Wegovy formulation is expected at higher doses (25 or 50 mg) approved for weight loss.
Will insurance cover oral Wegovy?
Commercial coverage is likely to mirror injectable Wegovy when available. Medicare will likely apply the same weight-loss exclusion unless the patient qualifies under a cardiovascular or other non-weight indication.
Why is semaglutide so expensive?
Semaglutide is still on-patent, manufacturing is complex, and demand has outstripped supply. Competition from tirzepatide and other GLP-1 agonists may pressure pricing in coming years.
The Bottom Line
Wegovy pill cost is expected to track closely with the injectable version at roughly $1,300 to $1,450 per month list price. Insurance and manufacturer savings programs will be the main ways to bring that down. Until the oral version launches, injectable Wegovy and Zepbound remain the primary weight-loss options. For cash-pay comparisons, see our articles on cheapest way to get Zepbound and Mounjaro price.